Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial
European Journal of Cancer2017Vol. 87, pp. 122–130
Citations Over TimeTop 10% of 2017 papers
Loïc Verlingue, David Malka, Adrien Allorant, Christophe Massard, Charles Ferté, Ludovic Lacroix, Étienne Rouleau, Nathalie Auger, Maud Ngo, Claudio Nicotra, Thierry de Baère, Lambros Tselikas, Bakar Ba, Stefan Michiels, Jean‐Yves Scoazec, Valérie Boige, Michel Ducreux, Jean‐Charles Soria, Antoine Hollebecque
Related Papers
- → Capecitabine Extends Survival for Biliary Tract Cancer(2017)16 cited
- → Reevaluating Adjuvant Capecitabine for Resected Biliary Tract Cancer(2023)3 cited
- → 6615 Advanced biliary tract cancer in Peruvian population(2009)
- → Supplementary Figure S2 from Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04)(2023)
- → MO34-1 Real-world evidence of precision medicine for biliary tract cancer(2023)